Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
14.71 USD
-0.88%
Market Closed
Updated:
Apr 28, 2024
Y-mAbs Therapeutics Inc
Cash from Operating Activities
|
Y-mAbs Therapeutics Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Cash from Operating Activities
-$27.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Y-mAbs Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-27.2m
USD
-27.2m
USD
Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's Cash from Operating Activities amounts to -27.2m USD.
What is Y-mAbs Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
8%
8%
Over the last year, the Cash from Operating Activities growth was 64%. The average annual Cash from Operating Activities growth rates for Y-mAbs Therapeutics Inc have been 33% over the past three years , 8% over the past five years .
You don't have any saved screeners yet
